From catalytic asymmetric synthesis to the transcriptional regulation of genes: 
In vivo and in vitro evolution of proteins

Barbas III, Carlos F:; Rader , Christopher; Segal, David J.; List, Benjamin; Turner, James M.

doi:10.1016/S0065-3233(01)55008-1

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

書籍の一部

From catalytic asymmetric synthesis to the transcriptional regulation of genes: In vivo and in vitro evolution of proteins

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Barbas III, C. F., Rader, C., Segal, D. J., List, B., & Turner, J. M. (2001). From catalytic asymmetric synthesis to the transcriptional regulation of genes: In vivo and in vitro evolution of proteins. In F. H., Arnold (Ed.), Advances in Protein Chemistry, Vol. 55: Evolutionary Protein Design (pp. 317-366). New York: Academic Press.

引用: https://hdl.handle.net/11858/00-001M-0000-0019-D60E-A

要旨

This chapter focuses on the laboratory use of molecular evolution and discusses the selection to shape the novel proteins of defined function. The chapter discusses the types of function that involve the antibody/antigen interactions of the classical type (simple binding), the nonclassical type (catalysis), and the molecular recognition of long DNA addresses in complex genomes. The ability to manipulate the expression of specific endogenous genes would have wide-ranging applications in medicine and experimental and applied biology. In the therapy of cancer, for example, oncogenes, angiogenic factors, metastatic factors, and drug resistance genes are all potential targets for down regulation, while tumor suppressors, immunostimulants, and apoptotic factors could be targets for specific up regulation. Transcription factors are modular proteins consisting typically of a DNA-binding domain that provides for localization of the protein to a specific DNA address, and an effector domain that directs the type of activity to take place at the site. The wide range of effector activities available provide significant advantages over other proposed technologies.